Logo image of BIOT

BIOTECH ACQUISITION CO-CL A (BIOT) Stock Fundamental Analysis

NASDAQ:BIOT - Nasdaq - KYG1125A1085 - Common Stock - Currency: USD

10.15  -0.08 (-0.78%)

After market: 10.19 +0.04 (+0.39%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BIOT. BIOT was compared to 0 industry peers in the Unkown industry. While BIOT seems to be doing ok healthwise, there are quite some concerns on its profitability. BIOT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BIOT had positive earnings in the past year.
In the past year BIOT has reported a negative cash flow from operations.
BIOT Yearly Net Income VS EBIT VS OCF VS FCFBIOT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 -2M -4M -6M

1.2 Ratios

Industry RankSector Rank
ROA 3.47%
ROE 3.68%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIOT Yearly ROA, ROE, ROICBIOT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 -10 -20 -30 -40

1.3 Margins

BIOT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIOT Yearly Profit, Operating, Gross MarginsBIOT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for BIOT has been increased compared to 1 year ago.
BIOT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BIOT Yearly Shares OutstandingBIOT Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 5M 10M 15M 20M 25M
BIOT Yearly Total Debt VS Total AssetsBIOT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 13.10 indicates that BIOT is not in any danger for bankruptcy at the moment.
BIOT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.1
ROIC/WACCN/A
WACCN/A
BIOT Yearly LT Debt VS Equity VS FCFBIOT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 0.03 indicates that BIOT may have some problems paying its short term obligations.
BIOT has a Quick Ratio of 0.03. This is a bad value and indicates that BIOT is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.03
Quick Ratio 0.03
BIOT Yearly Current Assets VS Current LiabilitesBIOT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 100K 200K 300K

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1296.12% over the past year.
EPS 1Y (TTM)1296.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIOT Yearly Revenue VS EstimatesBIOT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021
BIOT Yearly EPS VS EstimatesBIOT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 39.04 indicates a quite expensive valuation of BIOT.
BIOT is valuated rather expensively when we compare the Price/Earnings ratio to 29.62, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 39.04
Fwd PE N/A
BIOT Price Earnings VS Forward Price EarningsBIOT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOT Per share dataBIOT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BIOT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOTECH ACQUISITION CO-CL A

NASDAQ:BIOT (2/2/2023, 8:00:02 PM)

After market: 10.19 +0.04 (+0.39%)

10.15

-0.08 (-0.78%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap291.81M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 39.04
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.34
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)0.26
EY2.56%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS7.59
TBVpS7.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.47%
ROE 3.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.03
Quick Ratio 0.03
Altman-Z 13.1
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1296.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.12%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-200.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A